24 articles on longevity clinics in longevity medicine.
View all news →
Mayo Clinic Executive Health Program
Executive Health vs Longevity Clinic: Which Preventive Health Path Should You Choose in 2026?
A decision framework for choosing executive health, concierge prevention, or a longevity clinic in 2026 based on risk profile, diagnostics, follow-up, budget, and red flags.
Journal of Clinical Pharmacology: ACCP Position Statement on Hydration and Vitamin Infusion ClinicsPeer-reviewed
IV Nutrient Therapy at Longevity Clinics: Benefits, Costs, and Safety Questions
IV nutrient therapy can be clinically useful for selected deficiencies, but anti-aging claims are weaker. Here is how to compare clinics, costs, and safety protocols.
Lepodisiran, Muvalaplin, and the Lp(a) Moment: What New Cholesterol Drugs Mean for Longevity Clinics
Lepodisiran and muvalaplin are investigational Lp(a)-lowering drugs. For longevity clinics, the real 2026 action is smarter inherited cardiovascular risk screening.
FDA: Artificial Intelligence-Enabled Medical DevicesPeer-reviewed
The Longevity Clinic Tech Stack in 2026: Wearables, Biomarker Dashboards, AI Imaging, and the EMR Gap
A practical buyer guide to the 2026 longevity clinic tech stack: wearables, biomarker dashboards, AI imaging, EMR integration, privacy, aftercare, and the questions serious patients should ask before booking.
Ars Technica: RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 banPeer-reviewed
Peptide Therapy at Longevity Clinics: What's Legal, What Works & What's Next (2026)
Peptide therapy is the fastest-growing treatment category at longevity clinics. But RFK Jr.'s push to reclassify 12 banned peptides has created confusion. Here's which peptides clinics actually use, what the evidence says, what they cost, and how to choose a clinic.
LADbible: Joe Rogan shares bizarre image as he reveals what has been 'pulled out of his blood'
Joe Rogan Tries Plasmapheresis at Austin Longevity Clinic — What Is It, and Should You Consider It?
Joe Rogan underwent plasmapheresis at Ways2Well in Austin, calling it 'changing the oil in your body.' The FDA-approved procedure is gaining traction in longevity clinics. Here's what it is, the evidence, costs, and whether it's right for you.
Spannr: Peptide Therapy for Longevity: Benefits, Risks, and What's Real
Best Longevity Clinics for Peptide Therapy in 2026
With FDA peptide reclassification restoring access to 14 key peptides, longevity clinics offering peptide therapy are seeing renewed interest. Here's what to look for in a peptide clinic, which peptides are commonly offered, and how to evaluate quality and safety.
Los Angeles Emerges as the Capital of Longevity Startups: What the LA Times Found
The LA Times maps how Southern California has become a longevity industry hub — where biotech labs, venture capital, AI diagnostics, and concierge medicine are converging around healthspan extension.
Longevity Clinics: Evidence-Based Medicine or Cash-Pay Experimentation?
A critical analysis of the 'longevity clinic' phenomenon: serious prevention and offerings with limited evidence coexist. The challenge is separating signal from noise.
The Washington Post on Longevity Medicine's Boom: Big Promises, Uncertain Evidence
The Washington Post investigates the longevity medicine boom — from biohacking expos to high-end clinics — finding that commercial fervor has outpaced both scientific evidence and federal regulation.
2025 in Review: The Year Longevity Medicine Stopped Being Theoretical
A comprehensive review of 2025's longevity milestones: AI-driven drug deals, clinic proliferation, biomarker standardization, and the XPRIZE Healthspan competition reaching its final phase.
Longevity Clinics Get Their First Global Directory — And It Reveals How Fast the Industry Is Growing
Longevity.Technology launches Longevity Clinics World, a directory of 350+ pre-validated clinics globally. The move signals an industry maturing from niche to mainstream.
Longevity Clinics Between Promise and Peril: What a Leading Journal's Editor-in-Chief Thinks
An editorial in Aging by its Editor-in-Chief reviews the rapid rise of longevity clinics worldwide, highlighting both their potential for data-driven innovation and the serious risks of cost, standardization gaps, and scientific disconnect.